Primary and acquired resistance to AR-targeted therapies has been associated with mutations or amplification of AR gene (8, 16–18) and the expression of AR splice variants (i.e., AR-V7) in circulating tumor cells (CTC) or in metastatic tissues (19, 20). Here, AR is linked to neoplasm.